In summary, we identified the neoepitope ABL-E255V from secondary mutated CML and generated specific TCRs, in which the T9141-TCR was verified as a therapeutic candidate, as no off-target toxicity was detected. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.